These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 29205487)
1. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention. Lima FV; Gruberg L; Aslam U; Ramgadoo M; Clase K; Trevisan A; Jeremias A J Interv Cardiol; 2018 Apr; 31(2):177-184. PubMed ID: 29205487 [TBL] [Abstract][Full Text] [Related]
2. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P; Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988 [TBL] [Abstract][Full Text] [Related]
3. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice. Zhang Y; Zhang Y; Liu Z; Zhang B; Liu G; Chen K Biomed Pharmacother; 2020 Oct; 130():110758. PubMed ID: 34321166 [TBL] [Abstract][Full Text] [Related]
4. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials. Shah R; Matin K; Rogers KC; Rao SV Catheter Cardiovasc Interv; 2017 Aug; 90(2):196-204. PubMed ID: 27862911 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bivalirudin during percutaneous coronary intervention in high-bleeding-risk elderly patients with chronic total occlusion: A prospective randomized controlled trial. Wang Y; Zhao HW; Wang CF; Fan CY; Zhang XJ; Zhu Y; Luo DF; Yu GN; Hou AJ; Luan B Catheter Cardiovasc Interv; 2019 Feb; 93(S1):825-831. PubMed ID: 30724035 [TBL] [Abstract][Full Text] [Related]
6. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. Briguori C; Visconti G; Focaccio A; Donahue M; Golia B; Selvetella L; Ricciardelli B JACC Cardiovasc Interv; 2015 Mar; 8(3):414-423. PubMed ID: 25703878 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Shah R; Jovin IS; Chaudhry A; Haji SA; Askari R; Dennis MM; Berzingi C; Rao SV Catheter Cardiovasc Interv; 2019 Feb; 93(2):241-247. PubMed ID: 30269393 [TBL] [Abstract][Full Text] [Related]
8. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial. Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411 [TBL] [Abstract][Full Text] [Related]
9. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris. Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514 [TBL] [Abstract][Full Text] [Related]
10. Association between arterial access site and anticoagulation strategy on major bleeding and mortality: A historical cohort analysis in the Veteran population. Bagai J; Little B; Banerjee S Cardiovasc Revasc Med; 2018; 19(1 Pt B):95-101. PubMed ID: 28624360 [TBL] [Abstract][Full Text] [Related]
11. Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse hemorrhagic events by transradial access site and angioX) OCT study. Garcia-Garcia HM; Adamo M; Soud M; Yacob O; Picchi A; Sardella G; Frigoli E; Limbruno U; Rigattieri S; Diletti R; Boccuzzi G; Zimarino M; Contarini M; Russo F; Calabrò P; Andò G; Varbella F; Garducci S; Palmieri C; Briguori C; Karagiannis A; Valgimigli M Catheter Cardiovasc Interv; 2020 Nov; 96(6):1156-1171. PubMed ID: 31883294 [TBL] [Abstract][Full Text] [Related]
12. Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. Bangalore S; Pencina MJ; Kleiman NS; Cohen DJ Circ Cardiovasc Interv; 2014 Jun; 7(3):365-73. PubMed ID: 24736878 [TBL] [Abstract][Full Text] [Related]
13. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. Bangalore S; Cohen DJ; Kleiman NS; Regev-Beinart T; Rao SV; Pencina MJ; Mauri L; Circ Cardiovasc Interv; 2011 Oct; 4(5):463-73. PubMed ID: 21972401 [TBL] [Abstract][Full Text] [Related]
14. Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry. Washam JB; Kaltenbach LA; Wojdyla DM; Patel MR; Klein AJ; Abbott JD; Rao SV Circ Cardiovasc Interv; 2018 Feb; 11(2):e005628. PubMed ID: 29432119 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention. Rehmani A; Judkins C; Whelan A; Nguyen M; Schultz C Heart Lung Circ; 2017 Dec; 26(12):1277-1281. PubMed ID: 28377232 [TBL] [Abstract][Full Text] [Related]
16. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760 [TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes of Bivalirudin Versus Heparin in Elderly Patients Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Controlled Trials. Meng S; Xu J; Guo L; Huang R Cardiovasc Drugs Ther; 2020 Feb; 34(1):101-111. PubMed ID: 32100149 [TBL] [Abstract][Full Text] [Related]
19. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study. Kaul U; Dua A; Sethi AK; Arambam P; Seth A Indian Heart J; 2015; 67(4):311-7. PubMed ID: 26304562 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study. Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]